肝细胞癌的靶向治疗

Targeted therapies for hepatocellular carcinoma.

作者信息

Skelton Matthew R, O'Neil Bert

机构信息

Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

出版信息

Clin Adv Hematol Oncol. 2008 Mar;6(3):209-18.

PMID:18391920

Abstract

Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to traditional cytotoxic chemotherapy. The last 30 years of chemotherapy clinical trials for advanced HCC have repeatedly failed to demonstrate any survival benefit for a long list of drugs. However a survival advantage was recently established for sorafenib, instituting a new standard of care for unresectable HCC. Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs.

摘要

肝细胞癌（HCC）仍然是一种对传统细胞毒性化疗耐药的高致死性疾病。过去30年针对晚期HCC的化疗临床试验反复表明，众多药物均未能显示出任何生存获益。然而，最近索拉非尼确立了生存优势，为不可切除的HCC制定了新的治疗标准。在此，我们综述了近期及正在进行的针对HCC的新型治疗药物的研究，包括小分子酪氨酸激酶抑制剂、单克隆抗体以及这些药物的联合应用。